Theories of schizophrenia: A genetic-inflammatory-vascular synthesis

BMC Medical Genetics

Volumn 6, Issue , 2005, Pages

  Hanson, Daniel R ^a,b   Gottesman, Irving I ^b  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN CIRCULATION; BRAIN FUNCTION; BRAIN METABOLISM; CENTRAL NERVOUS SYSTEM DISEASE; DETERIORATION; DISEASE EXACERBATION; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; INFLAMMATORY DISEASE; MICROANGIOPATHY; NERVE CELL; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SYMPTOMATOLOGY; SYNAPSE; THEORETICAL MODEL; ANIMAL; BIOLOGICAL MODEL; BLOOD VESSEL; BRAIN; CAPILLARY; GENETIC PREDISPOSITION; GENETICS; INFLAMMATION; VASCULARIZATION;

ANIMALS; BLOOD VESSELS; BRAIN; CAPILLARIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; MODELS, NEUROLOGICAL; SCHIZOPHRENIA;

EID: 26444506864     PISSN: 14712350     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-6-7     Document Type: Review

References (262)

1. Faust D: The Limits of Scientific Reasoning. Minneapolis: University of Minnesota Press; 1984.
2. Wicker A: Getting out of our conceptual ruts: strategies for expanding conceptual frameworks. Am Psychol 1985, 40:1094-1103.
3. Gottesman II, Shields J, Hanson DR: Schizophrenia: the epigenetic puzzle. Cambridge: Cambridge University Press; 1982.
4. Manji H, Gottesman II, Gould T: Signal transduction and genesto-behaviors pathways in psychiatric diseases. Sci STKE 2004, 207:Pe49.
5. Petronis A: The origin of schizophrenia: Genetic thesis, epigenetic antithesis, and resolving synthesis. Biol Psychiatry 2004, 55:142-146.
6. Weinberger D, McClure R: Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry 2002, 59:553-558.
7. Matthew A, Murray R: Schizophrenia: a neurodevelopmental or neurodegenerative disorder? Curr Opin Psychiatry 2002, 15:9-15.
8. Lewis D, Levitt P: Schizophrenia as a disorder of neurodevelopment. Ann Rev Neurosci 2002, 25:409-432.
9. Church S, Cotter D, Bramon E, Murray R: Does schizophrenia result from developmental or degenerative processes? J Neural Transm Suppl 2002, 63:129-147.
10. McGrath J, Feron F, Burne T, Mackay-Sim A, Eyles D: The neurodevelopmental hypothesis of schizophrenia: a review of recent developments. Ann Med 2003, 35:86-93.
11. Korenberg J, Kawashima H, Pulst S, Allen L, Magenis E, Epstein C: Down syndrome: toward a molecular definition of the phenotype. Am J Med Genet Suppl 1990, 7:91-97.
12. Opitz J, Gilbert-Barness E: Reflections on the pathogenesis of Down syndrome. Am J Hum Genet Suppl 1990, 7:38-51.
13. Head E, Lott I: Down syndrome and beta-amyloid deposition. Curr Opin Neurol 2004, 17:95-100.
14. Bleuler E: Dementia Praecox or the Group of Schizophrenias. New York: International University Press; 1911.
15. Kraepelin E: Dementia Praecox and Paraphrenia. Edinburgh: E & S Livingston; 1919.
16. Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R: Prior juvenile diagnoses in adults with mental disorder. Arch Gen Psychiatry 2003, 60:709-717.
17. Erlenmeyer-Kimling L: Neurobehavioral deficits in offspring of schizophrenic parents. Am J Med Genet 2000, 97:65-71.
18. Niemi L, Suvisaari J, Tuulio-Henriksson A, Lonnqvist J: Childhood developmental abnormalities in schizophrenia: evidence from high risk studies. Schizophr Res 2003, 60:239-258.
19. Erlenmeyer-Kimling L, Roberts S, Rock D: Longitudinal prediction of schizophrenia in a prospective high-risk study. In Behavior Genetic Principles: Perspectives in Development, Personality, and Psychopathology Edited by: DiLalla LF. Washington, D.C.: American Psychological Association; 2004:135-144.
20. Hanson DR, Gottesman II: The genetics, if any, of infantile autism and childhood schizophrenia. J Autism Child Schizophr 1976, 6:209-234.
21. Slater E, Cowie V: The Genetics of Mental Disorders. London: Oxford University Press; 1971.
22. Cosway R, Byrne M, Clafferty R, Hodges A, Grant E, Abukmeil S, Lawrie S, Miller P, Johnstone E: Neuropsychological change in young people at high risk for schizophrenia: results from the fist two neuropsychological assessments of the Edinburgh High Risk Study. Psychol Med 2000, 30:1111-1121.
23. Gunnell D, Harrison G, Rasmussen F, Fouskakis D, Tynelius P: Association between premorbid intellectual performance, early life exposures and early-onset schizophrenia. Br J Psychiatry 2002, 181:298-305.
24. Friedman J, Harvey P, Coleman T, Moriarty P, Bowie C, Parrella M, white L, Adler D, Davis K: Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. Am J Psychiatry 2001, 158:1441-1448.
25. Zammit S, Allebeck P, David A, Dlaman C, Hemmingsson T, Lundberg I, Lewis G: A longitudinal study of premorbid IQ score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. Arch Gen Psychiatry 2004, 61:354-360.
26. Keri S, Janka Z: Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia. Acta Psychiatr Scand 2004, 110:83-91.
27. Keller A, Castellanos F, Vaituzis A, Jeffries N, Giedd J, Rapoport J: Progressive loss of cerebellar volume in childhood-onset schizophrenia. Am J Psychiatry 2003, 160:128-133.
28. Mathalon D, Sullivan E, Lim K, Pfefferbaum A: Progressive brain volume changes and the clinical course of schizophrenia. Arch Gen Psychiatry 2001, 58:148-157.
29. Niznikiewicz M, Kubicki M, Shenton M: Recent structural and functional imaging findings in schizophrenia. Curr Opin Psychiatry 2003, 16:123-147.
30. Stevens J: Anatomy of schizophrenia revisited. Schizophr Bull 1997, 23:373-383.
31. Garey L, Ong W, Patel T, Kanani M, Davis A, Mortimer A, Barnes T, Hirsch S: Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry 1998, 65:446-453.
32. Senitz D, Winkelmann E: Neuronal strukturanormalitat im orbito-frontalen cortex bei schizophrenien. J Hirnforsch 1991, 32:149-158.
33. Picchini A, Manji H, Gould T: GSK-3 and neurotropic signaling: novel targets underlying the pathophysioplogy and treatment of mood disorders? Drug Discovery Today: Disease Mechanisms. 2004, 1:419-428.
34. Cotter D, Pariante C, Everall I: Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001, 55:589-595.
35. Rosenthal D: The Genain Quadruplets: A Case Study and Theoretical Analysis of Heredity and Environment in Schizophrenia. New York: Basic Books; 1963.
36. Bleuler M: The Schizophrenic Disorders: Long-term Patient and Family Studies. New Haven: Yale University Press; 1978.
37. Schiffman J, Ekstrom M, La Brie J, Schulsinger F, Sorensen H, Mednick S: Minor physical anomalies and schizophrenia spectrum disorders: a prospective investigation. Am J Psychiatry 2002, 159:238-243.
38. McNeil TF, Cantor-Graae E: Minor physical anomalies and obstetric complication in schizophrenia. Aust N Z J Psychiatry 2000, 34:S65-73.
39. Hata K, Iida J, Iwasaka H, Negoro H, Kishimoto T: Association between minor physical anomalies and lateral ventricular enlargement in childhood and adolescent schizophrenia. Acta Psychiatr Scand 2003, 108:147-151.
40. Guy J, Majorski L, Wallace C, Guy M: The incidence of minor physical anomalies in adult male schizophrenics. Schizophr Bull 1983, 9:571-582.
41. Buckley P: The clinical stigmata of aberrant neurodevelopment in schizophrenia. J Nerv Ment Dis 1998, 186:79-86.
42. Hennesy R, Lane A, Kinsella A, Larkin C, O'Callaghan E, Waddington J: 3D morphometrics of craniofacial dysmorphology reveals sex-specific asymmetries in schizophrenia. Schizophr Res 2004, 67:261-268.
43. Maricq H: Capillary pattern in familial schizophrenics: a study of nailfold capillaries. Circulation 1963, 27:406-413.
44. Curtis CE, Iacono WG, Beiser M: Relationships between nailfold plexus visibility and clinical, neuropsychological, and brain structural measures in schizophrenia. Biol Psychiatry 1999, 46:102-109.
45. Vinogradov S, Gottesman II, Moises HW, Nicol S: Negative association between schizophrenia and rheumatoid arthritis. Schizophr Bull 1991, 17:669-678.
46. Cardno A, Gottesman II: Twin studies of schizophrenia: from bow-and-arrow concordance to Star Wars Mx and functional genomics. Am J Med Genet 2000, 97:12-17.
47. Hanson DR: Getting the bugs into our genetic theories of schizophrenia. In Behavior Genetic Principals Perspectives in Development, Personality, and Psychopathology Edited by: DiLalla L. Washington, D.C.: American Psychiatric Press; 2004:205-216.
48. Meehl P: Specific etiology and other forms of strong influence: Some quantitative meanings. J Med and Philos 1977, 2:33-53.
49. Yolken RH, Torrey EF: Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995, 8:131-145.
50. Yolken RH, Karlsson H, Yee F, Torrey EF: Endogenous retroviruses and schizophrenia. Brain Res Rev 2000, 31:193-199.
51. Harrison P: The neuropathology of schizophrenia: A critical review of the data and their interpretation. Brain 1999, 122:593-624.
52. Rothermundt M, Arolt V, Bayer T: Review of immunological and immunopathological finding in schizophrenia. Brain Behav Immun 2001, 15:319-339.
53. Rothermundt M, Peters M, Prehn J, Arolt V: S100B in brain damage and neurodegeneration. Microsc Res Tech 2003, 60:614-632.
54. Rothermundt M, Ponath G, Arolt V: S100B in schizophrenic psychosis. Int Rev Neurobiol 2004, 59:445-470.
55. Rothermundt M, Falaki P, Ponath G, Abel S, Burkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, et al.: Glial cell dysfunction in schizophrenia indicate by increased S100B in the CSF. Mol Psychiatry 2004, 9:897-899.
56. Pellerin S, Therianos S, Magistretti P: The metabolic function of glial cells. In Glial Cell Development 2nd edition. Edited by: Jessen K, Richardson W. Oxford: Oxford University Press; 2001:91-107.
57. Kurosinski P, Gotz J: Glial cells under physiologic and pathologic conditions. Arch Neurol 2002, 59:1524-1528.
58. Haydon P: GLIA: listening and talking to the synapse. Nat Rev Neurosci 2001, 2:185-193.
59. Coyle J, Schwarcz R: Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry 2000, 57:90-93.
60. Zonta M, Angulo M, Gobbo S, Rosengarten B, Hossmann K, Pozzan T, Carmignoto G: Neuron-to-astrocyte signaling is central to dynamic control of brain microcirculation. Nat Neurosci 2003, 6:43-50.
61. Medhora M, Narayanan J, Harder D: Dual regulation of the cerebral microvasculature by epoxyeicosatrienoic acids. Trends Cardiovasc Med 2001, 11:38-42.
62. Abott N: Astrocyte-endothelial interactions and blood-brain permeability. J Anatomy 2002, 200:629-638.
63. Virgintino D, Robertson D, Errede M, Benagiano V, Tauer U, Roncali L, Bertossi M: Expression of caveolin-1 in human brain microvessels. Neuroscience 2002, 115:145-152.
64. Paulson O: Blood-brain barrier, brain metabolism and cerebral blood flow. Eur Neuropsychopharmacol 2002, 12:465-501.
65. Yoder E: Modifications in astrocyte morphology and calcium signaling induced by a brain capillary endothelial cell line. Glia 2002, 38:137-145.
66. Gallo V, Ghiani C, Yuan X: The role of ion channels and neurotransmitter receptors in glial cell development. In Glial Cell Development 2nd edition. Edited by: Jessen K, Richardson W. Oxford: Oxford University Press; 2001:110-130.
67. Harder D, Zhang C, Gebremedhin D: Astrocytes function in matching blood flow to metabolic activity. News Physiol Sci 2002, 17:27-31.
68. Cohen Z, Bouchelet I, Olivier A, Villemure J, Ball R, Stanimirovic D, Hamel E: Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J Cereb Blood Flow Metab 1999, 19:908-917.
69. Elhusseiny A, Cohen Z, Olivier A, Stanimirovic D, Hamel E: Functional acetylcholine muscarinic receptor subtypes in human brain microcirculation: identification and cellular localization. J Cereb Blood Flow Metab 1999, 19:794-802.
70. Favard C, Simon A, Vigny A, Nguyen-Legros J: Ultrastructural evidence for a close relationship between dopamine cell process and blood capillary walls in Macaca monkey and rat retina. Brain Res 1990, 523:127-133.
71. Bacic F, Uematsu S, McCarron RM, Spatz M: Dopamine receptors linked to adenylate cyclase in human cerebromicrovascular endothelium. J Neurochem 1991, 57:1774-1780.
72. Cavaglia M, Dombrowski S, Drazba J, Vasanji A, Bokesch P, Janigro D: Regional variation in brain capillary density and vascular response to ischemia. Brain Res 2001, 910:81-93.
73. Harrison R, Harel N, Panesar J, Mount R: Blood capillary distribution correlates with hemodynamic-based functional imaging in cerebral cortex. Cereb Cortex 2002, 12:225-233.
74. Risau W, Esser S, Engelhardt B: Differentiation of blood-brain barrier endothelial cells. Pathol Biol 1998, 46:171-175.
75. Sasaki R: Pleiotropic functions of erythropoietin. Intern Med 2003, 42:142-149.
76. Shusta EV, Boado RJ, Mathern GW, Pardridge WM: Vascular genomics of the human brain. J Cereb Blood Flow Metab 2002, 22:245-252.
77. Virgintino D, Errede M, Robertson D, Girolamo F, Masciandaro A, Bertossi M: VEGF expression is developmentally regulated during brain angiogenesis. Histochem Cell Biol 2003, 119:227-232.
78. Schiera G, Bono E, Raffa MP, Gallo A, Pitarresi GL, Di Liegro I, Savett G: Synergistic effects of neurons and astrocytes on the differentiation of brain capillary endothelial cells in culture. J Cell Mol Med 2003, 7:165-170.
79. Zhang C, Harder DR: Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocyte epoxyeicosartrienoic acid. Stroke 2002, 33:2957-2964.
80. Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, Kim YJ, Kim K: SSeCKS regulates angiogenesis and tight junction formation in the blood-brain barrier. Nat Med 2003, 9:828-829.
81. Senitz D, Benninghoff J: Histomorphology of angiogenesis in human perinatal orbitofrontal cortex: a Golgi and electron microscopic study of anastomosis formation. Anat Embryol 2003, 206:479-485.
82. Richter T, Ronald P: The evolution of disease resistant genes. Plant Mol Biol 2000, 42:195-204.
83. Mackenzie K, Bishop S: Utilizing stochastic genetic epidemiological models to quantify the impact of selection for resistance to infectious diesease in domestic livestock. J Anim Sci 2001, 79:2057-2065.
84. Kallmann FJ, Reisner D: Twin studies on the genetic variation in resistance to tuberculosis. J Hered 1943, 34:293-301.
85. Werneck-Barroso E: Innate resistance to tuberculosis: revisiting Max Lurie genetic experiments in rabbits. Int J Tuberc Lung Dis 1999, 3:166-168.
86. McGue M, Gottesman II, Rao DC: The transmission of schizophrenia under a multifactorial threshold model. Am J Hum Genet 1983, 35:1161-1178.
87. Bion JF, Brun-Buisson C: Introduction - infection and critical illness: genetic and environmental aspects of susceptibility and resistance. Intensive Care Med 2000:S1-S2.
88. Burt RA: Genetics of host response to malaria. Int J Parasitol 1999, 29:973-979.
89. Hawken RJ, Beattie CW, Schook LB: Resolving the genetics of resistance to infectious diseases. Rev Sci Tech 1998, 17:17-25.
90. Hill AV: Genetics of infectious disease resistance. Curr Opin Genet Dev 1996, 6:348-353.
91. Hill AV: Genetics and genomics of infectious disease susceptibility. Br Med Bull 1999, 55:401-413.
92. Seymour RM: Some aspects of the coevolution of virulence and resistance in contact transmission processes with ecological constraints. IMA J Math Appl Med Biol 1995, 12:83-136.
93. Kitagawa M, Aizawa S, Ikeda H, Hirokawa W: Establishment of a therapeutic model for retroviral infection using the genetic resistance mechanism of the host. Pathol Int 1996, 46:719-725.
94. Smith DA, Germolec DR: Introduction of immunology and autoimmunity. Environ Health Perspect 1999, 107:661-665.
95. Blackwell JM: Genetics and genomics of infectious disease susceptibility. Trends Mol Med 2001, 7:521-526.
96. Knight J: Polymorphisms in tumor necrosis factor and other cytokines as risks for infectious disease and the septic shock syndrome. Curr Infect Dis Rep 2001, 3:427-439.
97. Cook GS, Hill AV: Genetics of susceptibility to human infectious disease. Nat Rev Genet 2001, 2:967-977.
98. Beskow AH, Gyllensten UB: Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri. Int J Cancer 2002, 101:526-531.
99. Wang FS: Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J Gastroenterol 2003, 9:641-644.
100. Touitou I: The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 2001:473-483.
101. Scholl P: Periodic fever syndromes. Curr Opin Pediatr 2000, 12:563-566.
102. Ozen S: Vasculopathy, Bechets Syndrome and familial Mediterranean fever. Curr Opin Rheumatol 1999, 11:393-398.
103. Tutar E, Akar N, Atalay S, Yilmaz E, Akar E, Yalcinkaya F: Familial Mediterranean fever gene (MEFV) mutations in patients with rheumatic heart disease. Heart 2002, 87:568-569.
104. Veasy LG, Hill HR: Immunologic and clinical correlations in rheumatic fever and rheumatic heart disease. Pediatr Infect Dis J 1997, 16:400-407.
105. Yegin O, Coskun M, Ertug H: Cytokines in acute rheumatic fever. Eur J Pediatr 1997, 156:25-29.
106. Shore P, Jackson E, Wisniewski S, Clark R, Adelson P, Kochanek P: Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children. Neurosurgery 2004, 54:605-611.
107. Curristin S, Cao A, Stewart W, Zhang H, Madri J, Morrow J, Ment L: Disrupted synaptic development in the hypoxic newborn brain. Proc Natl Acad Sci USA 2002, 99:15729-15734.
108. Zang W, Smith C, Howlett C, Stanimirovic D: Inflammatory activation of human brain endothelial cells by hypoxic astrocytes in vitro is mediated by IL-1[beta]. J Cereb Blood Flow Metab 2000, 20:967-978.
109. Dietrich P-Y, Walker P, Saas P: Death receptors on reactive astrocytes: a key role in the fine tuning of brain inflammation. Neurology 2003, 60:548-554.
110. Meeuwsen S, Persoon-Dean C, Bsibis M, Ravid R, Van Noort J: Cytokine, chemokine, and growth factor gene profiling of cultured human astrocytes after exposure to proinflammatory stimuli. Glia 2003, 43:243-253.
111. Croitoru-Lamoury J, Guillemin G, Boussin F, Mognetti B, Gigout L, Cheret A, Vaslin B, LeGrand R, Brew B, Dormont D: Expression of chemokines and their receptors in human and simian astrocytes: evidence for a central role of TNFα and IFNγ in CXCR4 and CCR5 modulation. Glia 2003, 41:354-370.
112. Rubenstein G: Schizophrenia, rheumatoid arthritis and natural disease resistance. Schizophr Res 1997, 25:177-181.
113. Morris JA: Schizophrenia, bacterial toxins and the genetics of redundancy. Med Hypotheses 1996, 46:362-366.
114. Munk-Jorgensen P, Ewald H: Epidemiology in neurobiological research: exemplified by the influenza-schizophrenia story. Br J Psychiatry Suppl 2001, 40:S30-S32.
115. O'Reilly SL, Singh SM: Retroviruses and schizophrenia revisited. Am J Med Genet 1996, 67:19-26.
116. Torrey EF, Miller J, Rawlings R, Yolken RH: Seasonality of births in schizophrenia and bipolar disorder: A review of the research. Schizophr Res 1997, 28:1-38.
117. Davison K, Bagley C: Schizophrenia-like psychoses associated with organic disorders of the central nervous system: A review of the literature. In Current Problems in Neuropsychiatry: Schizophrenia, Epilepsy, the Temporal Lobe Edited by: Herrington R. Ashford, Kent, UK: Headley Brothers; 1969.
118. Beadles C: On the degenerative lesions of the arterial system in the insane, with remarks upon the nature of the granular ependyma. J Ment Sci 1895, 41:32-50.
119. Bender L: Psychiatric, neurologic and neuropathologic studies in disseminated alterative arteriolitis. Arch Neurol Psychiatry 1936, 36:790-815.
120. Hess D: Cerebral lupus vasculopathy. Mechanisms and clinical relevance. Ann NY Acad Sci 1997, 823:154-168.
121. Lass P, et al.: Cerebral blood flow in Sjogren's syndrome using 99Tcm-HMPAO brain SPET. Nucl Med Commun 2000, 21:31-35.
122. Fredericks R, Lefkowitz D, Challa V, Troost B: Cerebral vasculitis associated with cocaine abuse. Stroke 1991, 22:1437-1439.
123. Shi X, Wu J, Liu Z, Tang J, Su Y: Single photon emission CT perfusion imaging of cerebral blood flow in early syphilis patients. Chin Med J (Engl) 2003, 116:1051-1054.
124. Thomas A, et al.: Ischemic basis for deep white matter hyperintensities in major depression. Arch Gen Psychiatry 2002, 59:785-792.
125. Kronfol Z, Remick DG: Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000, 157:683-694.
126. Wang H, Yu M, Oschanl M, Amella C, Tanovic M, Susarla S, Li J, Wang H, Yang H, Ulloa L, et al.: Nicotinic acetylcholine receptor alpha subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
127. Chorsky R, Yaghamai F, Hill W, Stopa E: Alzheimer's disease: a review concerning immune response and microischemia. Med Hypotheses 2001, 56:124-127.
128. Farkas E, De Jong G, Apro E, De Vos R, Steur E, Luiten P: Similar ultrastructural breakdown of cerebrocortical capillaries in Alzheimer's disease, Parkinson's disease, and experimental hypertension. What is the functional link? Ann N Y Acad Sci 2000, 903:72-82.
129. Farkas E, Luiten P: Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001, 64:575-611.
130. Versijpt J, Van Laere K, Dierckx R, Dumont F, De Deyn P, Slegers G, Korf J: Scintigraphic visualization of inflammation in neurodegenerative disorders. Nucl Med Commun 2003, 24:209-221.
131. Grammas P: A damaged microcirculation contributes to neuronal cell death in Alzheimer's disease. Neurobiol Aging 2000, 21:199-205.
132. de La Torre J: Critically attained threshold of cerebral hypoprofusion: Can it cause Alzheimer's disease? Ann N Y Acad Sci 2000, 903:424-436.
133. Preston S, Steart P, Wilkinson A, Nicoll J, Weller R: Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid [beta] from the human brain. Neuropathol Appl Neurobiol 2003, 29:106-117.
134. Borroni B, Akkawi N, Martini G, Colciaghi F, Prometti P, Rozzinin L, Di Luca M, Lenzi G, Romanelli G, Caimi L, et al.: Microvascular damage and platelet abnormalities in early Alzheimer's disease. J Neurol Sci 2002, 203-204:189-193.
135. Vagnucci AHJ, Li WW: Alzheimer's disease and angiogenesis. Lancet 2003, 361:605-608.
136. Gibson C, MacLennan A, Goldwater P, Dekker G: Antenatal causes of cerebral palsy: associations between inherited thrombophilias, viral and bacterial infection, and inherited susceptibility to infection. Obstet Gynecol Surv 2003, 58:209-220.
137. Lee Y, Henning B, Yao J, Toborek M: Methamphetamine induces AP-1 and NF-kappaB binding and transactivation in human brain endothelial cells. J Neurosci Res 2001, 66:583-591.
138. Lignelli G, Buchheit W: Angitis in drug abusers. N Engl J Med 1971, 284:112-113.
139. Rumbaugh C, Bergeron R, Fang H, McCormik R: Cerebral angiographic changes in the drug abuse patient. Radiology 1971, 101:335-344.
140. Citron B, Halpern M, McCarron M, Lundberg G, McCormick R, Pincus I, Tatter D, Haverback B: Necrotizing angitis associate with drug abuse. N Engl J Med 1970, 283:1003-1011.
141. Behzadian MA, Wang XL, Shabrawey M, Caldwell RB: Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-beta. Glia 1998, 24:216-225.
142. Dammann O, Leviton A: Brain damage in preterm newborns: might enhancement of developmentally regulated endogenous protection open the door for prevention? Pediatrics 1999, 104:541-550.
143. Molinero A, Penkowa M, Hernandez J, Camats J, Giralt M, Lago N, Carrasco J, Campbell IL: Matallothionein-I over expression decreased brain pathology in transgenic mice with astrocyte-targeted expression of interleukin-g. J Neuropathol Exp Neurol 2003, 62:315-328.
144. Proescholdt MA, Heiss JD, Walbridge S, Muhlhauser J, Capogrossi MC, Oldfield EH, Merrill MJ: Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol 1999, 58:613-627.
145. Penkowa M, Carrasco J, Giralt M, Molinero A, Hernandez J, Campbell IL, Hidalgo J: Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallotioein- I=II deficient mice. J Cereb Blood Flow Metab 2000, 20:1174-1189.
146. Kirk SL, Karlik SJ: VEGF and vascular changes in chronic neuroinflammation. J Autoimmun 2003, 21:353-363.
147. Olsen NV: Central nervous system frontiers for the use of erythropoietin. Clin Infect Dis 2003, 37:S323-S330.
148. Yang RB, Ng CK, Wasserman SM, Colman SD, Shenoy S, Mehraban F, Komuves LG, Tomlinson JE, Topper JN: Identification of a novel family of cell-surface proteins expressed in human vascular endothelium. J Biol Chem 2002, 277:46364-46373.
149. Cannon M, Jones P, Murray RM: Obstetric complications and schizophrenia: Historical and meta-analytic review. Am J Psychiatry 2002, 159:1080-1092.
150. Gilmore J, Jarskog L, Vadlamudi S, Lauder J: Prenatal infection and risk for schizophrenia: IL-Iβ, IL-6, and TNFα inhibit cortical neuron dendrite development. Neuropsychopharmacology 2004, 29:1221-1229.
151. Mueller N, Riedel M, Hadjamu M, Schwarz M, Ackenheil M, Gruber R: Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 1999, 156:634-636.
152. Kety S, Schmidt C: The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure and normal values. J Clin Invest 1948, 27:476-483.
153. Kety SS, Woodford RB, Harmel MH, Freyman FA, Appel KE, Schmidt CF: Cerebral blood blow and metabolism in schizophrenia. Am J Psychiatry 1948, 104:765-770.
154. Williamson P: Hypofrontality in schizophrenia: a review of the evidence. Can J Psychiatry 1987, 32:399-404.
155. Weinberger DR, Berman KF: Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr Bull 1988, 14:157-168.
156. Semkovska M, Bedard MA, Stip E: Hypofrontalite et symptomes nefatifs dans la schizophrenie: syntheses des acquis anatomiques et neuropsychologiques et neuropsychologiques et perspectives ecologiques. Encephale 2001, 27:405-415.
157. Honey G, Fletcher P, Bullmore E: Functional brain mapping of psychopathology. J Neurol Neurosurg Psychiatry 2002, 72:432-439.
158. Hofer A, Weiss E: Advances in the neuroimaging of cognitive functions in schizophrenia. Curr Opin Psychiatry 2002, 15:3-7.
159. Bachneff S: Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Schizophr Bull 1996, 22:163-182.
160. Andreasen N, O'Leary D, Flaum M, Nopoulos P, Watkins G, Ponto L, Hichwa R: Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 1997, 349:1730-1734.
161. Barch C, Carter C, Braver T, Sabb F, MacDonald A, Noll D, Cohen J: Selective deficits in prefrontal cortex function in medicationnaive patients with schizophrenia. Arch Gen Psychiatry 2001, 58:280-288.
162. Kim JJ, Mohamed S, Andreasen NC, Oleary DS, Watkins GL, BolesPonto LL, Hichwa RD: Regional neural dysfunctions in chronic schizophrenia studied with positive emission tomography. Am J Psychiatry 2000, 157:542-548.
163. Miller D, Rezai K, Alliger R, Andreasen N: The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography. Biol Psychiatry 1997, 41:550-559.
164. Vaiva G, Llorca P, Dupont S, Cottencin O, Devos P, Mazas O, Rascle C, Steinling M, Goudemand M: Spect imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res 2002, 115:37-48.
165. Lahti A, Holcomb H, Weiler M, Medoff D, Tamminga C: Functional effects of antipsychotic drugs: comparing clozapine and haloperidol. Biol Psychiatry 2003, 53:601-608.
166. Miller D, Andreasen N, O'Leary D, Watkins G, Boles Ponto L, Hichwa R: Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol Psychiatry 2001, 49:704-715.
167. Lahti A, H Holcomb, Medoff D, Weiler M, Tamminga C, Carpenter W: Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry 2001, 158:1797-1808.
168. Vaiva G, Cottencin O, Llorca P, Devos P, Dupont S, Mazas O, Tascle C, Thomas P, Steinling M, Goudemand M: Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:481-485.
169. Ashton L, Barnes A, Livingston M, Wyper D: Cingulate abnormalities associated with PANSS negative scores in first episode schizophrenia. Behav Neurol 2000, 12:93-101.
170. Franck N, O'Leary D, Flaum M, Hichwa R, Andreasen N: Cerebral blood flow changes associated with Schneiderian first-rank symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci 2002, 14:277-282.
171. Paradiso S, Andreasen N, Crespo-Facorro B, O'Leary D, Watkins G, Boles Ponto L, Hichwa R: Emotions in unmedicated patients with schizophrenia during evaluation with positron emission tomography. Am J Psychiatry 2003, 160:1175-1783.
172. Meyer-Lindberg A, Miletich R, Kohn P, Esposito G, Carson R, Quarantelli M, D W, Berman K: Reduced prefrontal activity predicts exaggerated striatal dopominergic function in schizophrenia. Nat Neurosci 2002, 5:267-271.
173. Callicott J, Bertolino A, Mattay V, Langheim F, Duyn J, Coppola R, Goldberg T, Weinberger D: Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000, 10:1078-1092.
174. 15O PET adds fundamental new information on differences in cognitive activation between schizophrenics and healthy control subjects. J Nucl Med 2003, 44:671-681.
175. Busatto GF, Zamignani DR, Buchpiguel CA, Garrido GE, Glabus MF, Rocha ET, Maia AF, Rosario-Campos MC, Campi Castro C, Furuie SS, et al.: A voxel-based investigation of regional cerebral blood flow abnormalities in obsessive-compulsive disorder using single photon emission computed tomography (SPECT). Psychiatry Res 2000, 99:15-27.
176. Lesser IM, Mena I, Boone KB, Miller BL, Mehringer CM, Wohl M: Reduction of cerebral blood flow in older depressed patients. Arch Gen Psychiatry 1994, 51:677-686.
177. Liotti M, Mayberg HS, McGinnis S, Brannan SL, Jerabek P: Unmasking disease-specific cerebral blood flow abnormalities: Mood challenge in patients with remitted unipolar depression. Am J Psychiatry 2002, 159:1830-1840.
178. Swedo S, et al.: High prevalence of obsessive-compulsive symptoms in patients with Sydenham's Chorea. Am J Psychiatry 1989, 146:246-249.
179. Swedo SE, Leonard HL, Kiessling LS: Speculations on antineuronal antibody-mediated neuropsychiatric disorders of childhood. Pediatrics 1994, 93:323-326.
180. Asbahr F, Negrao A, Gentil V, Zanetta D, da Paz J, Marques-Dias M, Kiss M: Obsessive compulsive and related syndromes in children and adolescents with rheumatic fever with and without chorea: a prospective 6 month study. Am J Psychiatry 1998, 155:1122-1124.
181. Garvey MA, Swedo SE: PANDAS: the search for environmental triggers of pediatric neuropsychiatric disorders. Lessons from rheumatic fever. J Child Neurol 1998, 13:413-423.
182. Bottas A, Richer MA: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). Pediatr Infect Dis J 2002, 21:67-71.
183. Moore D: Neuropsychiatric aspects of Sydenham's Chorea. J Clin Psychiatry 1996, 57:407-414.
184. Mercadante M, Busatto GF, Lombroso P, Prado L, Rosario-Campos M, do Valle R, Marques-Dias M, Kiss M, Leckman J, Miguel EC: The psychiatric symptoms of rheumatic fever. Am J Psychiatry 2000, 157:2036-2038.
185. Davison K, Bagley CR: Schizophrenia-like psychoses associated with organic disorders of the central nervous system: A review of the literature. In Current Problems in Neuropsychiatry British Journal of Psychiatry Special Publication No. 4 Edited by: Herrington RN. Ashford, Kent: Headley Brothers; 1969.
186. Van Der Horst L: Rheumatism and psychosis. Foli Psychiatr Neurol Neurochir Neerl 1948, 1/2:54-56.
187. Bruetsch W: The histopathology of the psychoses with subacute bacterial and chronic verrucose rheumatic endocarditis. Amer J Psychiatry 1938, 95:335-346.
188. Winkelman N, Eckel JL: The brain in acute rheumatic fever. Arch Neurol Psychiatry 1932:844-870.
189. Dublin W: Pathologic lesions of the brain associated with chronic rheumatic endocarditis and accompanied by psychosis. Dis Nerv Syst 1941:390-393.
190. Bruetsch W: Rheumatic endarteritis of cerebral vessels: sequel of rheumatic fever. Trans Am Neurol Assoc 1942, 68:17-20.
191. Van Der Horst L: Rheuma und psychose. Arch Psychiatr Nervenkr 1949, 181:325-336.
192. Lewis A, Minski L: Chorea and psychosis. Lancet 1935:536-538.
193. Skvortsova E: Clinical neuropsychiatric changes during rheumatism. Klin Med 1956, 34:25-32.
194. Hammes E: Psychoses associated with Sydenham's Chorea. JAMA 1922, 79:804-807.
195. Howie D: Some pathological findings in schizophrenics. Am J Psychiatry 1960, 117:59-62.
196. Shaskan D: Mental changes in chorea minor. Am J Psychiatry 1938, 95:193-202.
197. Bruetsch W: Chronic rheumatic brain disease as a possible factor in the causation of some cases of dementia praecox. Am J Psychiatry 1940, 97:276-296.
198. Keeler WR, Bender L: A follow-up study of children with behavior disorders and Sydenham's chorea. Am J Psychiatry 1952, 169:421-428.
199. Wertheimer N: A psychiatric follow-up of children with rheumatic fever and other chronic diseases. J Chronic Dis 1963, 16:223-237.
200. Wilcox J, Nasrallah H: Sydenham's chorea and psychopathology. Neuropsychobiology 1988, 19:6-8.
201. Guttmann E: On some constitutional aspects of chorea and on its sequelae. Journal of Neurology and Psychopathology 1936, 17:16-26.
202. Bruetsch W: Late cerebral sequele of rheumatic fever. Arch Intern Med 1944, 73:972-982.
203. Wertheimer N: "Rheumatic schizophrenia". Arch Gen Psychiatry 1961, 4:579-596.
204. Wilcox J, Nasrallah H: Sydenham's chorea and psychosis. Neuropsychobiology 1986, 15:13-14.
205. Hanson DR: Streptococcal infections and psychoses? A preliminary inquiry. In Infectious Diseases and Neuropsychiatric Disorders Edited by: Fatemi SH. London: Martin Dunitz; 2005 in press.
206. Costero I: Cerebral lesions responsible for death of patients with active rheumatic fever. Arch Neurol Psychiatry 1949, 62:48-72.
207. Bompiani G, Benedetti E, Cecconi D: Arteriopathie cerebrali reumatiche. Arch Ital Anat Istol Pathol 1954, 28:1-35.
208. Bini L, Giovanni M: Uber den chronischen cerebralrheumatismus. Arch Psychiat Nervenkr 1952, 188:261-273.
209. Mitkov V: Cerebral manifestations of rheumatic fever. World Neurol 1961, 2:920-927.
210. Mueller N, Ackenheil M: Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: Relationship to negative symptomatology. Schizophr Res 1995, 14:223-228.
211. Carreno-Manjarrez R, Visvanathan K, Zabriskie J: Immunogenic and genetic factors in rheumatic fever. Curr Infect Dis Rep 2000, 2:302-307.
212. Fish B: Neurobiologic antecedents of schizophrenia in children: Evidence for an inherited, congenital neurointegrative defect. Arch Gen Psychiatry 1977, 34:1297-1313.
213. Meehl P: Schizotaxia, schizotypy, schizophrenia. Am Psychol 1962, 17:827-838.
214. Moises HM, Zoega T, Gottesman II: The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry 2002 [http://www.biomedcentral.com/1471-244X/2/8].
215. Prabakaran S, Swatton J, Ryan M, Huffaker S, Huang J, Griffin J, Wayland M, Freeman T, Dudbridge F, Lilley K, et al.: Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004, 9:684-697. Epub Apr 20
216. Yao J, Reddy R, van Kammen D: Oxidative damage and schizophrenia: an overview of the evidence. CNS Drugs 2001, 15:287-310.
217. Mahadik S, Scheffer R: Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1996, 55:45-54.
218. Mooradian A: The antioxidative potential of cerebral microvessels in experimental diabetes mellitus. Brain Res 1995, 671:164-169.
219. Calingasan N, Park L, Calo L, Trifiletti R, Gandy S, Gibson G: Induction of nitric oxide synthase and microglial response precede selective cell death induced by chronic impairment of oxidative metabolism. Am J Pathol 1998, 153:599-610.
220. Mooradian A, Akon U: Age-related changes in the antioxidative potential of cerebral microvessels. Brain Res 1995, 671:159-163.
221. Schwarz M, Ackenheil M, Riedel M, Mueller N: Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci Lett 1998, 253:201-203.
222. Buka S, Tsuang M, Fuller-Torrey E, Klebanoff M, Bernstein D, Yolken R: Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 2001, 58:1032-1037.
223. Zornberg G, Buka S, Tsuang M: Hypoxia-ischemia-related fetal/neonatal complications and risk of schizophrenia and other nonaffective psychoses: a 19-year longitudinal study. Am J Psychiatry 2000, 157:196-202.
224. Brown A, Hooton J, Schaefer C, Zhang H, Petkova E, Babulas V, Perrin M, Gorman J, Susser E: Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 2004, 161:889-895.
225. Findlay G, Harris W: The topology of hair streams and whorls in man, with an observation on their relationship to epidermal ridge patterns. Am J Phys Anthropol 1977, 46:427-437.
226. Furdon S, Clark D: Scalp hair characteristics in the newborn infant. Adv Neonatal Care 2003, 3:286-296.
227. Detmar M, Brown L, B B, Jackman R, Elicker B, Dvorak H, Claffey K: Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 1997, 108:263-268.
228. Futamura T, Toyooka K, Iritani S, Nilzato K, Nakamura R, Tsuchiya K, Someya T, Kakita A, Takahashi H, Nawa H: Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry 2002, 7:673-682.
229. Merrill JT: Regulation of the vasculature: clues from lupus. Curr Opin Rheumatol 2002, 14:504-509.
230. Ekdahl CT, Claasen J-H, Bonde S, Kokaia Z, Lindvall O: Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003, 100:13632-13637.
231. Dinc A, Melikoglu M, Korkmaz C, Fresko I, Ozdogan H, Yazidi H: Nailfold capillary abnormalities in patients with familial Mediterranean fever. Clin Exp Rheumatol 2001, 19:s42-s44.
232. den Broeder A, van den Hoogren F, van de Putte L: Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumor necrosis factor alpha blocking treatment. Ann Rheum Dis 2001, 60:538-539.
233. Stollerman GH: Rheumatic fever. Lancet 1997, 349:935-942.
234. Bisno A, Pearce I, Wall H, Moody M, Stollerman GH: Contrasting epidemiology of acute glomerulonephritis: nature of the antecedent streprococcal infection. N Engl J Med 1970, 283:561-565.
235. Smoot J, Barbian K, Van Gompel J, Smoot L, Chaussee M, Sylva G, Sturdevant D, Ricklefs S, Porcella S, Parkins L, et al.: Genome sequence and comparative microarray analysis of serotype M18 group A Streptococcus strains associated with acute rheumatic fever outbreaks. Proc Natl Acad Sci USA 2002, 99:4668-4673.
236. Boin F, Zanardini R, Pioli R, Altamura C, Maes M, Gennarelli M: Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 2001, 6:79-82.
237. Schwab S, Mondabon S, Knapp M, Albus M, Hallmayer J, Borrmann-Hassenbach M, Trixler M, Gross M, Schulze T, Rietschel M, et al.: Association of tumor necrosis factor alpha gene -G308A polymorphisms with schizophrenia. Schizophr Res 2003, 65:19-25.
238. Katila H, Hanninen K, Hurme M: Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol Psychiatry 1999, 4:179-181.
239. Erbagci A, Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M: Serum IL-1beta, sIL-2r, IL-6, IL-8, and TNF alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 2001, 10:109-115.
240. Moots R, Al-Saffer Z, Hutchinson D, Golding S, Young S, Bacon P, McLaughlin P: Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis 1999, 58:585-587.
241. Leykin I, Mayer R, Shinitzky M: Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997, 37:75-86.
242. Maes M, Bocchio C, Bignotti S, Battisa T, Pioli R, Boin F, Kenix G, Bosmans E, de Jongh R, Lin A, et al.: Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 2000, 10:119-124.
243. Marek J: On the non-specific anitinflammatory effects of other-than-anitrheumatic drugs. Psychotropic drugs, inflammation and antiinflammatory drugs. Int J Tissue React 1985, 7:475-504.
244. Rudolf S, Peters M, Rothermundt M, Arolt V, Kirchner H: The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interfreron-gamma in vitro. Neuropsychobiology 2002, 46:180-185.
245. Mueller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel R, Moller H, Schwartz M: Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002, 159:1029-1034.
246. McGuffin P, Asherson P, Owen M, Farmer A: The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? Br J Psychiatry 1994, 164:593-599.
247. Moises H, Gottesman I: Genetics, risk factors, and personality factors. In Contemporary Psychiatry Edited by: Henn F, Helmchen H, Lauter H, Sartorius N. Heidelberg: Springer Verlag; 2000:47-59.
248. Turkheimer E: Spinach and ice cream: why social science is so difficult. In Behavior Genetics Principles: Perspective in Development, Personality, and Psychopathology Edited by: DiLalla L. Washington, D.C.: American Psychological Association; 2004:161-189.
249. Gottesman II, Shields J: A polygenic theory of schizophrenia. Proc Natl Acad Sci USA 1967, 58:199-205.
250. Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M, Woldt H, Falki P, Knerlich F, Jacob S, et al.: Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 2004:1-13.
251. Tsao B, Grossman J, Riemekasten G, Strong N, Kalsi J, Wallace D, Chen C-J, Lau C, Ginzler E, Goldstein R, et al.: Familiality and co- occurrence of clinical features of systemic lupus erythematosus. Arthritis Rheum 2002, 46:2678-2685.
252. Dysken M, Patlak C, Dobben G, Pettigrew K, Bartko J, Burns E, Davis J, Refier D: Rapid dynamic CT scanning to distinguish schizophrenic from normal subjects. Psychiatry Res 1987, 20:165-175.
253. Mueller N, Ackenheil M: Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22:1-33.
254. Harrison P, Weinberger D: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-68.
255. Rosenthal D: Genetic Theory and Abnormal Behavior. New York: McGraw-Hill; 1970:162-168.
256. Schumacher J, Abon Jamra R, Freudenber J, Becker T, Ohiarun S, Otte A, Tullius M, Kovalenko S, Van Den Bogaert A, Maier W, et al.: Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry 2004, 9:203-207.
257. Maziade M, Roy M-A, Chagnon Y, Cliche D, Fournier J-P, Montgrain N, Dion C, Lavallee J-C, Garneau Y, Gingras N, et al.: Shared and specific susceptibility loci for schizophrenia and bipolar disorder: a genome scan in Eastern Quebec families. Mol Psychiatry 2004, Nov 9 (e-pub):1-14.
258. Rajkowska G: Cell pathology in bipolar disorder. Semin Clin Neuropsychiatry 2002, 7:281-292.
259. Muller M, Lucassen P, Yassouridis H, Hoogendijk W, Holsboer F, Swaab D: Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci 2001, 14:1603-1612.
260. Gottesman I, Hanson D: Human Development: Biological and genetic processes. Annu Rev Psychol 2005, 56:263-286.
261. Huleihel M, Golan H, Hallak M: Intrauterine infection/inflammation during pregnancy and offspring brain damages: possible mechanisms involved. Reprod Biol Endocrinol 2004 [http://www.rbej.com/content/2/1/17].
262. Gottesman I, Gould T: The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003, 160:636-645.